Skip to main content
OpenTrials
Completed

NCT Number: NCT04837261

Shortening Duration of Antiarrhythmic Medication for SVT in Infants

The infants diagnosed with SVT are treated with antiarrhythmic medication to prevent the recurrence of SVT. This prospective observational cohort study evaluates efficacy and safety of shortening duration of antiarrhythmic medication to four months in infants with SVT. Primary outcome is incidence of recurrent SVT in infants after 4 months of antiarrhythmic medication compared to retrospectively reviewed cohort.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Supraventricular Tachycardia Arrhythmias, Cardiac Cardiac Conduction System Disease Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Tachycardia Tachycardia, Supraventricular

Age range

Up to 6 month

Sex eligibility

All sexes

Study type

Observational

Primary location

Central Finland Central Hospital, Jyväskylä, Central Finland, Finland

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 6 months or less
  • Documented SVT due to AVRT or AVNRT

Exclusion criteria

  • Age > 6 months
  • Ectopic atrial tachycardia
  • Atrial flutter
  • Atrial fibrillation
  • Permanent junctional reciprocating tachycardia

Treatment and study plan

Propranolol

Drug

3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months

Flecainide

Drug

80 mg/m2/d

Amiodarone

Drug

Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d

Primary outcomes

  1. Recurrence of SVT after antiarrhythmic medication

    Time frame: 1 year follow-up

Secondary outcomes

  1. Proportion of participants with treatment failure

    Time frame: 4 months of antiarrhythmic medication

  2. Prevalence of adverse events

    Time frame: 4 months of antiarrhythmic medication

  3. Recurrence of SVT after one year follow-up

    Time frame: 5 year

Sponsors and collaborators

Lead sponsor

Tampere University Hospital

Other

Collaborators

  • Helsinki University Central Hospital
  • Kuopio University Hospital
  • Oulu University Hospital
  • Turku University Hospital

Registry information

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Apr 8, 2021
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.